Edition:
United States

Merck's treatment for urinary tract infection wins FDA approval


Wednesday, 17 Jul 2019 06:45am EDT 

July 17 (Reuters) - Merck & Co Inc ::FDA APPROVES MERCK’S RECARBRIO™ (IMIPENEM, CILASTATIN, AND RELEBACTAM) FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT AND COMPLICATED INTRA-ABDOMINAL BACTERIAL INFECTIONS WHERE LIMITED OR NO ALTERNATIVE TREATMENT OPTIONS ARE AVAILABLE.FDA APPROVES MERCK’S RECARBRIO™ (IMIPENEM, CILASTATIN, AND RELEBACTAM) FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT AND COMPLICATED INTRA-ABDOMINAL BACTERIAL INFECTIONS WHERE LIMITED OR NO ALTERNATIVE TREATMENT OPTIONS ARE AVAILABLE.MERCK & CO INC - APPROVAL OF THESE INDICATIONS IS BASED ON LIMITED CLINICAL SAFETY AND EFFICACY DATA FOR RECARBRIO..MERCK & CO INC - MERCK ANTICIPATES MAKING RECARBRIO AVAILABLE LATER THIS YEAR..MERCK & CO INC - FDA APPROVED RECARBRIO FOR INJECTION, 1.25 GRAMS.MERCK & CO - RECARBRIO SHOULD BE USED ONLY TO TREAT OR PREVENT INFECTIONS THAT ARE PROVEN OR STRONGLY SUSPECTED TO BE CAUSED BY SUSCEPTIBLE BACTERIA.